Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 7/20 | 0.66 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.66 |
| ▸ | PSMB2 | P49721 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.64 |
| ▸ | LTA4H | P09960 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ACACB | O00763 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11154787 | 1.00 | PSMB1 (0.66) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| SCHEMBL10897426 | 0.99 | PSMB1 (0.63) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| SCHEMBL2741674 | 0.87 | PSMB1 (0.68) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| SCHEMBL2741675 | 0.87 | PSMB1 (0.68) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| SCHEMBL10897064 | 0.86 | ALDH1A1 (0.67) | KDM4EHRH3LTA4HACACB | |
| SCHEMBL12315758 | 0.86 | KDM4E (0.63) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL228735 | 0.86 | PSMB1 (0.66) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL228395 | 0.86 | PSMB1 (0.66) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| SCHEMBL7240783 | 0.85 | PSMB1 (0.65) | PSMB1PSMB5PSMB2KDM4EHRH3 | |
| SCHEMBL16379389 | 0.85 | PSMB1 (0.61) | PSMB1PSMB5PSMB2KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2009-07-16 | — | — | US | disclosed |
| US-7358376-B2 | Substituted Thiophene compounds | ASTRAZENECA AB (SE) | 2008-04-15 | — | — | US | disclosed |
| EP-1261600-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| EP-1261600-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | disclosed |
| WO-2001058890-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
| US-5604225-A | DIETETICS; OBESITY | DR. KARL THOMAE GMBH (DE) | 1997-02-18 | — | — | US | disclosed |
| US-5457205-A | Substituted thiazoles useful for treatment of diabetes | DR. KARL THOMAE GMBH (DE) | 1995-10-10 | — | — | US | disclosed |
| US-5219852-A | Hypoglycemic agents, treatment of diabetes and obesity | DR. KARL THOMAE GMBH (DE) | 1993-06-15 | — | — | US | disclosed |
| EP-0239815-B1 | SUBSTITUTED THIAZOLES AND OXAZOLES, MEDICINES CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | Dr. Karl Thomae GmbH (DE) | 1991-07-24 | — | — | EP | disclosed |
| US-4886814-A | LOWER BLOOD SUGAR | DR. KARL THOMAS GMBH (DE) | 1989-12-12 | — | — | US | disclosed |
| EP-0239815-A1 | Substituted thiazoles and oxazoles, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1987-10-07 | — | — | EP | disclosed |
| EP-0070133-B1 | SECONDARY PHENYLETHANOL AMINES, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL APPLICATION | BEECHAM GROUP PLC (GB) | 1986-05-14 | — | — | EP | disclosed |
| EP-0070133-A2 | Secondary phenylethanol amines, processes for their preparation and their pharmaceutical application | BEECHAM GROUP PLC (GB) | 1983-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ABCG2, SULT1E1, TPMT | PSMB1 3466/4885PSMB5 2173/4885PSMB2 2987/4885 |
| US-20020107252-A1 | Novel Compounds | UGT1A1, CYP1B1, CYP1A1 | PSMB1 2588/4885PSMB5 2008/4885PSMB2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.